JAN 15, 2020 8:06 AM PST

Hope for patients with AML

Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may be able to be used in order to reverse treatment resistance in patients with acute myeloid leukemia (AML). AML is one of the most common forms of blood cancer, with an incidence of over 20,000 cases in the US annually.

The research comes from scientists at Karolinska Institutet and SciLifeLab, who conducted their initial investigations in mice and human blood cells and will soon begin a clinical trial in humans.

The team of researchers figured out a cocktail of substances that aid in inhibiting the effects of an enzyme called SAMHD1 on the conventionally used drug cytarabine (ara-C). Cytarabine, while already in use to treat AML, is only marginally effective because many patients’ high levels of SAMHD1 break down the key metabolite that makes the drug work. Hence, the researchers hypothesized that blocking SAMHD1 might make cytarabine more effective.

The cocktail they identified includes three different substances of ribonucleotide reductase inhibitors (RNRi): hydroxyurea, gemcitabine and triapine. "Adding any of these three substances significantly improved the effectiveness of the cytarabine-treatment in cell samples with high levels of SAMHD1," says Nikolas Herold, a researcher at the Department of Women's and Children's Health at Karolinska Institutet in Sweden. "This was true for AML samples from both adults and children. In AML-mice, we also saw that the median survival was significantly prolonged when cytarabine was combined with an RNR-inhibitor."

A commonly used inexpensive drug could help leukemia patients, suggests new research. Photo: Pixabay

The good news is that these substances are already somewhat known for their anti-cancer potency. The researchers are putting a lot of focus on hydroxyurea, in particular, because it is inexpensive, and as Herold says, "Hydroxyurea is an approved drug that is already used to treat AML, so we think it has great potential.” He continues, referring to the team’s future endeavors: “If our research results can be confirmed in clinical trials, the treatment of AML could be significantly improved also in developing countries with limited resources since hydroxyurea is patent-free and doesn't cost more than ibuprofen."

The researchers will be working with the Swedish AML-group to start recruiting patients for their clinical study within a matter of weeks.

Sources: EMBO Molecular Medicine, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
SEP 16, 2020
Cancer
I'm addicted to the sun, are you?
SEP 16, 2020
I'm addicted to the sun, are you?
New research published in the Journal of Investigative Dermatology reports evidence that some people are geneticall ...
OCT 08, 2020
Cancer
Oral cancer pain levels indicate metastasis
OCT 08, 2020
Oral cancer pain levels indicate metastasis
A new study from NYU College of Dentistry researchers provides insight as to why patients with metastatic oral cancer ex ...
OCT 19, 2020
Cancer
Using qPCR to Diagnose Common Cancer Mutations in Lung Cancer
OCT 19, 2020
Using qPCR to Diagnose Common Cancer Mutations in Lung Cancer
Cancer is a disease characterized by DNA mutations. These mutations, while sometimes small, can cause havoc in a cell&rs ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 20, 2020
Cancer
How does tissue geometry influence cancer cellular migration?
NOV 20, 2020
How does tissue geometry influence cancer cellular migration?
A team of researchers led by UC Santa Barbara's Distinguished Professor Denise Montell has recently published new fi ...
Loading Comments...